White spotting variant mouse as an experimental model for ovarian aging and menopausal biology

Menopause

Volumn 19, Issue 5, 2012, Pages 588-596

  Smith, Elizabeth R ^a   Yeasky, Toni ^a   Wei, Jain Qin ^b   Miki, Roberto A ^c   Cai, Kathy Q ^d   Smedberg, Jennifer L ^d   Yang, Wan Lin ^d   Xu, Xiang Xi ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Miami Hand Center   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

C kit; Germ cells; Menopause; Mouse model; Ovarian follicles; Wv mice

Indexed keywords

CALCIUM; CHOLESTEROL; ESTROGEN; GONADOTROPIN; HORMONE; LIPID; LIPOPROTEIN; PHOSPHOTRANSFERASE; PROGESTERONE; STEM CELL FACTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CARDIOMEGALY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ESTROGEN BLOOD LEVEL; FEMALE; GERM CELL; GONADOTROPIN BLOOD LEVEL; HEART DISEASE; HEART FUNCTION; HEART WEIGHT; HORMONE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; MOUSE; MOUSE STRAIN; NEWBORN; NONHUMAN; OVARIAN AGING; OVARY DEVELOPMENT; OVARY FOLLICLE; OVARY FUNCTION; POINT MUTATION; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; WHITE SPOTTING VARIANT MOUSE; WILD TYPE;

AGING; ANIMALS; BODY COMPOSITION; BONE DENSITY; CHOLESTEROL; ESTROGENS; FEMALE; GONADOTROPINS; HEART; HUMANS; LIPOPROTEINS; MENOPAUSE; MICE; MODELS, ANIMAL; MYOCARDIUM; ORGAN SIZE; OVARIAN FOLLICLE; OVARY; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84860773378     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318239cc53     Document Type: Article

References (66)

1. Finn CA. Reproductive ageing and the menopause. Int J Dev Biol 2001;45:613-617.
2. Gao J, Tiwari-Pandey R, Samadfam R, et al. Altered ovarian function affects skeletal homeostasis independent of the action of folliclestimulating hormone. Endocrinology 2007;148:2613-2621.
3. Erickson GF. Ovarian anatomy and physiology. In: Lobo RA, Kelsey J, Marcus R, eds. Menopause: Biology and Pathobiology. San Diego, CA: Academic Press, 2000:13-31.
4. Gold EB. Demographics, environmental influences, and ethnic and international differences in the menopausal experience. In: Lobo RA, Kelsey J, Marcus R, eds. Menopause: Biology and Pathobiology. San Diego, CA: Academic Press, 2000:189-201.
5. Gosden RG, ed. Biology of Menopause: The Causes and Consequences of Ovarian Ageing. London, UK: Academic Press, 1985.
6. Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 1996;7:1484-1486.
7. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428.
8. Sherwin BB. Estrogen and cognitive function in women. Endocr Rev 2003;24:133-151.
9. Stopeck AT. Women's health: the struggle to restore hormonal balance. Am J Med 2005;118:1181-1182.
10. Wise PM. New understanding of the complexity of the menopause and challenges for the future. In: Bellino FL, ed. Sereno Symposia U.S.A: Biology of Menopause. New York, NY: Springer-Verlag, 2000:1-8.
11. Cai KQ, Klein-Szanto A, Karthik D, et al. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol 2006;103:719-728.
12. Nicosia SV. The aging ovary. Med Clin North Am 1987;71:1-9.
13. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf ) 1998; 49:695-707.
14. Tortolero-Luna G, Mitchell ME. The epidemiology of ovarian cancer. J Cell Biochem Suppl 1995;23:200-207.
15. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1995;71(2 suppl):517-523.
16. Smith ER, Xu XX. Etiology of epithelial ovarian cancer: a cellular mechanism for the role of gonadotropins. Gynecol Oncol 2003;91:1-2.
17. Smith ER, Daly MB, Xu XX. A mechanism for COX-2 inhibitor antiinflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev 2004;13:144-145.
18. Raisz LG. Pathogenesis of osteoporosis: concepts, conflict, and prospects. J Clin Invest 2005;115:3318-3325.
19. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302.
20. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14:411-415.
21. Baron R. FSH versus estrogen: who's guilty of breaking bones? Cell Metabol 2006;3:302-305.
22. Williams GR. Hypogonadal bone loss: sex steroids or gonadotropins? Endocrinology 2007;148:2610-2612.
23. Zaidi M, Sun L, Kumar TR, Sairam MR, Blair HC. Both FSH and sex steroid influence bone mass. Cell 2006;127:180-181.
24. Kumar TR. Functional analysis of LHA knockout mice. Mol Cell Endocrinol 2007;269:81-84.
25. Chen WY. Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab 2008;22:573-585.
26. Rouach V, Katzburg S, Koch Y, Stern N, Somjen D. Bone loss in ovariectomized rats: dominant role for estrogen but apparently not for FSH. J Cell Biochem 2011;112:128-137.
27. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006;125:247-260.
28. Perez GI, Jurisicova A, Wise L, et al. Absence of the proapoptotic Bax protein extends fertility and alleviates age-related health complications in female mice. Proc Natl Acad Sci USA 2007;104:5229-5234.
29. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. The follicle-deplete mouse ovary produces androgen. Biol Reprod 2004;71:130-138.
30. Romero-Aleshire MJ, Diamond-Stanic MK, Hasty AH, Hoyer PB, Brooks HL. Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2009;297: R587-R592.
31. Lohff JC, Christian PJ, Marion SL, Hoyer PB. Effect of duration of dosing on onset of ovarian failure in a chemical-induced mouse model of perimenopause. Menopause 2006;13:482-488.
32. Danilovich N, Ram Sairam M. Recent female mouse models displaying advanced reproductive aging. Exp Gerontol 2006;41:117-122.
33. Little CC. The inheritance of black-eyed white spotting in mice. Am Nat 1915;49:727-740.
34. Mintz B, Russell ES. Gene-induced embryological modification of primordial germ cells in the mouse. J Exp Zool 1957;134:207-237.
35. Mintz B. Embryological development of primordial germ-cells in the mouse: influence of a new mutation, Wj. J Embryol Exp Morphol 1957; 5:396-403.
36. Dubreuil P, Rottapel R, Reith AD, Forrester L, Bernstein A. The mouse W/c-kit locus. A mammalian gene that controls the development of three distinct cell lineages. Ann N Y Acad Sci 1990;599:58-65.
37. Reith AD, Rottapel R, Giddens E, Brady C, Forrester L, Bernstein A. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 1990;4:390-400.
38. Nocka K, Tan JC, Chiu E, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 1990;9:1805-1813.
39. Yang WL, Cai KQ, Smedberg JL, et al. A reduction of Cox-2 gene dosage counters the menopausal ovarian morphological aging and tumor phenotype in Wv mice. Am J Pathol 2007;170:1325-1336.
40. Murphy ED. Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. J Natl Cancer Inst 1972;48: 1283-1295.
41. Murphy ED, Beamer WG. Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx-Wv genotype. Cancer Res 1973;33:721-723.
42. Kissell H, Timokhina I, Hardy MP, et al. Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses. EMBO J 2000;19:1312-1326.
43. Ohta H, Tohda A, Nishimune Y. Proliferation and differentiation of spermatogonial stem cells in the W/Wv mutant mouse testis. Biol Reprod 2003;69:1815-1821.
44. Kubota H, Avarbock MR, Schmidt JA, Brinster RL. Spermatogonial stem cells derived from infertile Wv/Wv mice self-renew in vitro and generate progeny following transplantation. Biol Reprod 2009;81:293-301.
45. Nagy TR, Clair AL. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 2000;8:392-398.
46. Kohler T, Stauber M, Donahue LR, Mueller R. Automated compartmental analysis for high-throughput skeletal phenotyping in femora of genetic mouse models. Bone 2007;41:659-667.
47. Reinwald S, Mayer LP, Hoyer PB, Turner CH, Barnes S, Weaver CM. A longitudinal study of the effect of genistein on bone in two different murine models of diminished estrogen-producing capacity. J Osteoporos 2010;2010:145170.
48. Turner CH. Bone strength: current concepts. Ann N Y Acad Sci 2006; 1068:429-446.
49. Levay AK, Peacok JD, Lu Y, et al. Sclerzxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res 2008;103:948-956.
50. Mayer LP, Dyer CA, Eastgard RL, Hoyer PB, Banka CL. Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. Arterioschler Throm Vasc Biol 2005;25:1910-1916.
51. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate myocardial balance of angiogenic cytokines. J Clin Invest 2006;116:1865-1877.
52. Gosden RG. Follicular status at menopause. Hum Reprod 1987;2:617-621.
53. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721.
54. Mohle J, Whittemore A, Pike M, Darby S. Gonadotrophins and ovarian cancer risk. J Natl Cancer Inst 1985;75:178-180.
55. Bone Health and Osteoporosis: A Report of the Surgeon General, 2004. Available at http://www.surgeongeneral.gov/library/bonehealth/content.html. Accessed April 7, 2011.
56. Yang XP, Rekelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 2011;20:133-138.
57. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
58. Pistner A, Belmonte S, Coulthard T, Blaxall B. Murine echocardiography and ultrasound imaging. J Vis Exp 2010;42:2100.
59. Rottman JN, Ni G, Brown M. Echocardiographic evaluation of ventricular function in mice. Echocardiography 2007;56:1025-1033.
60. The North American Menopause Society. Menopause Practice: A Clinician's Guide. Mayfield Heights, OH: NAMS, 2004. Available at: http://www.menopause.org. Accessed September 1, 2011.
61. Bhuiyan MS, Fukunaga K. Characterization of an animal model of postmenopausal cardiac hypertrophy and novel mechanism responsible for cardiac decompensation using ovariectomized pressure-overloaded rats. Menopause 2010;17:213-221.
62. Meites J, Lu JKH. Reproductive aging and neuroendocrine function. In: Charlton HM, ed. Oxford Reviews of Reproductive Biology. New York: Oxford University Press, 1994:215-247.
63. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Porcellati C. Early cardiac changes after menopause. Hypertension 1998;32:764-769.
64. Mendon'a Lde S, Fernandes-Santos C, Mandarim-de-Lacerda CA. Cardiac and aortic structural alterations due to surgically-induced menopause associated with renovascular hypertension in rats. Int J Exp Pathol 2007; 88:301-309.
65. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114: 763-776.
66. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.